Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial

BACKGROUND: We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513)....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Chron Obstruct Pulmon Dis
Päätekijät: Ismaila, Afisi S, Risebrough, Nancy, Schroeder, Melanie, Shah, Dhvani, Martin, Alan, Goodall, Emma C, Ndirangu, Kerigo, Criner, Gerard, Dransfield, Mark, Halpin, David MG, Han, MeiLan K, Lomas, David A
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2019
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6890193/
https://ncbi.nlm.nih.gov/pubmed/31819401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S216072
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia